Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade C 93.04 0.50% 0.46
ARGX closed up 0.5 percent on Thursday, July 19, 2018, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARGX trend table...

Date Alert Name Type % Chg
Jul 19 50 DMA Support Bullish 0.00%
Jul 19 MACD Bullish Centerline Cross Bullish 0.00%
Jul 19 Outside Day Range Expansion 0.00%
Jul 19 Overbought Stochastic Strength 0.00%
Jul 18 Stochastic Sell Signal Bearish 0.50%
Jul 18 50 DMA Support Bullish 0.50%
Jul 18 NR7 Range Contraction 0.50%
Jul 18 Inside Day Range Contraction 0.50%
Jul 18 Overbought Stochastic Strength 0.50%
Jul 17 Crossed Above 50 DMA Bullish -0.42%

Older signals for ARGX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
  • Earnings date: 2017-10-26
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 17 argenx receives milestone payment from strategic collaboration with Shire
Jun 29 Benzinga's Top Upgrades, Downgrades For June 29, 2018
Jun 28 argenx receives second preclinical milestone payment under its development agreement with AbbVie
Jun 20 Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
Jun 20 Argenx's efgartigimod shows encouraging action in mid-stage pemphigus vulgaris study
Jun 20 argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Jun 14 Argenx announces data from phase 1 study of ARGX-113
Jun 14 argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
Jun 12 argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018
Jun 11 21 Stocks Moving In Monday's Pre-Market Session
See more ARGX news...
Indicators
Indicator Value
52 Week High 103.0
52 Week Low 19.42
Average Volume 105,714
200-Day Moving Average 67.5941
50-Day Moving Average 91.8754
20-Day Moving Average 87.6435
10-Day Moving Average 89.427
Average True Range 2.797
ADX 20.43
+DI 27.8165
-DI 16.7394
Chandelier Exit (Long, 3 ATRs ) 86.079
Chandelier Exit (Short, 3 ATRs ) 90.796
Upper Bollinger Band 93.5906
Lower Bollinger Band 81.6964
Percent B (%b) 0.95
BandWidth 13.571115
MACD Line 0.1825
MACD Signal Line -0.8415
MACD Histogram 1.024
Fundamentals Value
Market Cap 2.5 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -73.26
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 98.10
Resistance 3 (R3) 97.66 95.52 97.26
Resistance 2 (R2) 95.52 94.23 95.75 96.98
Resistance 1 (R1) 94.28 93.44 94.90 94.73 96.70
Pivot Point 92.15 92.15 92.46 92.37 92.15
Support 1 (S1) 90.91 90.86 91.53 91.35 89.38
Support 2 (S2) 88.77 90.06 89.00 89.10
Support 3 (S3) 87.53 88.77 88.82
Support 4 (S4) 87.98